[177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial

Enzalutamide in Metastatic Prostate Cancer before Chemotherapy

Tomasz M. Beer, Andrew J. Armstrong, Dana E. Rathkopf et al. · New England Journal of Medicine · 2014 · 3K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer

Oliver Sartor, Johann S. de Bono, Kim N. et al. · New England Journal of Medicine · 2021 · 2.6K citations · Full text

Medicine, Oncology, Radiation Oncology +17

Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer

Ian D. Davis, Andrew Martin, Martin R. Stockler et al. · New England Journal of Medicine · 2019 · 1.6K citations

Pharmacy, Oncology, Pharmacotherapy +17

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

Michael S. Hofman, Louise Emmett, Shahneen Sandhu et al. · The Lancet · 2021 · 1.1K citations

Medicine, Oncology, Pharmacology +12

Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer

Alec Paschalis, Beshara Sheehan, Ruth Riisnaes et al. · European Urology · 2019 · 465 citations · Full text

Medicine, Oncology, Urology +17